Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 dec 2007 - 10:01
Statutaire naam
Crucell N.V.
Titel
DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with Medarex Inc.
Bericht
Sittard/Leiden, The Netherlands, December 18, 2007 – DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc. This license agreement allows Medarex to use the PER.C6® production platform in its antibody research. Financial details of the agreement were not disclosed.
Gerelateerde downloads
Datum laatste update: 22 december 2025